At a glance
ClinicalIndex Comparison RecordN/ACompleted· 732 enrolled
Drug / intervention
brimonidine tartrate/timolol maleate Ophthalmic Solutiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Combigan® Ophthalmic Solution in Korea
In Brief
An observational study evaluating brimonidine tartrate/timolol maleate Ophthalmic Solution for Glaucoma, Open-Angle and Ocular Hypertension. Completed, enrolled 732 participants across 1 site.
Detailed Summary
This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of Combigan® (brimonidine tartrate/timolol maleate) Ophthalmic Solution in patients with Open Angle Glaucoma or Ocular hypertension with insufficient response to local beta blockers treated as per standard of care in clinical practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Open-Angle, Ocular Hypertension
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2009
Primary CompletionNov 2011
First PostedNov 2013
TodayJul 2026
First PostedNov 19, 2013
Enrollment StartJan 1, 2009
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 12.6 years ago
Interventions
brimonidine tartrate/timolol maleate Ophthalmic Solutiondrug
brimonidine tartrate/timolol maleate (Combigan®) Ophthalmic Solution as per local standard of care in clinical practice.